These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28505195)

  • 1. Dose escalation study to evaluate safety, tolerability and efficacy of intravenous etoposide phosphate administration in 27 dogs with multicentric lymphoma.
    Boyé P; Serres F; Marescaux L; Hordeaux J; Bouchaert E; Gomes B; Tierny D
    PLoS One; 2017; 12(5):e0177486. PubMed ID: 28505195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma.
    Tierny D; Serres F; Segaoula Z; Bemelmans I; Bouchaert E; Pétain A; Brel V; Couffin S; Marchal T; Nguyen L; Thuru X; Ferré P; Guilbaud N; Gomes B
    Clin Cancer Res; 2015 Dec; 21(23):5314-23. PubMed ID: 26169968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days.
    Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C
    Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of etoposide phosphate (etopophos) as a 30-minute infusion on days 1, 3, and 5.
    Fields SZ; Igwemezie LN; Kaul S; Schacter LP; Schilder RJ; Litam PP; Himpler BS; McAleer C; Wright J; Barbhaiya RH
    Clin Cancer Res; 1995 Jan; 1(1):105-11. PubMed ID: 9815892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical and pharmacokinetic study of oral etoposide phosphate.
    Sessa C; Zucchetti M; Cerny T; Pagani O; Cavalli F; De Fusco M; De Jong J; Gentili D; McDaniel C; Prins C
    J Clin Oncol; 1995 Jan; 13(1):200-9. PubMed ID: 7799021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma.
    Thamm DH; Vail DM; Post GS; Fan TM; Phillips BS; Axiak-Bechtel S; Elmslie RS; Klein MK; Ruslander DA
    J Vet Intern Med; 2017 May; 31(3):872-878. PubMed ID: 28370378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early studies of etoposide phosphate, a water-soluble prodrug.
    Budman DR
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):8-14. PubMed ID: 8996570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.
    Budman DR; Igwemezie LN; Kaul S; Behr J; Lichtman S; Schulman P; Vinciguerra V; Allen SL; Kolitz J; Hock K
    J Clin Oncol; 1994 Sep; 12(9):1902-9. PubMed ID: 8083713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481).
    Millward MJ; Newell DR; Mummaneni V; Igwemezie LN; Balmanno K; Charlton CJ; Gumbrell L; Lind MJ; Chapman F; Proctor M
    Eur J Cancer; 1995 Dec; 31A(13-14):2409-11. PubMed ID: 8652278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
    Rutherford SC; Abramson JS; Bartlett NL; Barta SK; Khan N; Joyce R; Maddocks K; Ali-Shaw T; Senese S; Yuan Y; Westin J; Leonard JP
    Lancet Haematol; 2021 Nov; 8(11):e818-e827. PubMed ID: 34634256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of etoposide phosphate plus paclitaxel.
    Brooks DJ; Alberts DS
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):30-3. PubMed ID: 8996573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of pretreatment plasma D-dimer level in dogs with intermediate to high-grade non-Hodgkin lymphoma.
    Boyé P; Serres F; Floch F; Fournel-Fleury C; Tierny D
    Vet Comp Oncol; 2021 Mar; 19(1):44-52. PubMed ID: 32643242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors.
    Kreis W; Budman DR; Vinciguerra V; Hock K; Baer J; Ingram R; Schacter LP; Fields SZ
    Cancer Chemother Pharmacol; 1996; 38(4):378-84. PubMed ID: 8674162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials.
    Saba CF; Clifford C; Burgess K; Phillips B; Vail D; Wright Z; Curran K; Fan T; Elmslie R; Post G; Thamm D
    Vet Comp Oncol; 2020 Dec; 18(4):763-769. PubMed ID: 32346934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival.
    Valli VE; Kass PH; San Myint M; Scott F
    Vet Pathol; 2013 Sep; 50(5):738-48. PubMed ID: 23444036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of high dose etoposide phosphatase with filgrastim (G-CSF) in the treatment of advanced refractory malignancies.
    Hainsworth JD; Utley SM; Greco FA
    Invest New Drugs; 1997; 15(4):325-9. PubMed ID: 9547675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypersensitivity reactions to etoposide phosphate.
    Sambasivan K; Mahmoud S; Kokache A; Seckl M; Savage P
    J Oncol Pharm Pract; 2014 Apr; 20(2):158-60. PubMed ID: 23740378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical studies with etoposide phosphate.
    Greco FA; Hainsworth JD
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):45-50. PubMed ID: 8996575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.